Menu

Disclaimer

Terms of Access Agreement and Disclaimers

Welcome to the website of Oakley Capital Investments Limited (“OCI”) of Mintflower Place, 3rd Floor, 8 Par-la-Ville Road, Hamilton HM08, Bermuda. 

Users of this website are responsible for observing all applicable laws and regulations in their relevant jurisdictions before proceeding to access the information contained within it. By proceeding to access the information, users are deemed to be representing and warranting that the applicable laws and regulations of their relevant jurisdiction allow them to do so.

Jurisdictional scope

This website and its contents are only intended for persons in the UK and persons in any other jurisdiction to whom such information can lawfully be communicated without any authorisation, licence or approval being obtained. In particular, the information on this website is not directed at and is not for use by any US Person (as defined in Regulation S under the US Securities Act of 1933 (as amended) (“US Securities Act”)).

OCI has not been and will not be registered under the US Investment Company Act of 1940 (as amended) and, as such, holders of shares in OCI will not be entitled to the benefits of that Act. Shares in OCI have not been and will not be registered under the US Securities Act or with any securities regulatory authority of any state or other jurisdiction of the United States. Shares in OCI may not be offered or sold within the United States or to, or for the account or benefit of, US Persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require OCI to register under the US Investment Company Act of 1940 (as amended). Shares in OCI have not been, and will not be, registered under the securities laws, or with any securities regulatory authority, of any jurisdiction outside the UK.

Purpose of the website

This website is for information only. It is not an offer or invitation to buy or sell, or a solicitation of an offer to buy or sell, or a recommendation to buy or sell, any securities mentioned. Nothing on this website should be taken as an invitation or inducement to engage in any investment activity. Information on this website does not, and should not be deemed to, constitute investment, tax, legal or any other advice.

Investment Risk

The value of securities and any income from them may go down as well as up, and an investor may not get back the full amount of money invested. Past performance is not a reliable indicator or guarantee of future performance. There is no guarantee that the market price of OCI’s shares will fully reflect their underlying net asset value or that OCI’s investment objective will be achieved. You are strongly encouraged to seek individual advice from your professional adviser(s) before entering into any agreement to buy or sell any security or making any financial or investment decision.

Shares in OCI are traded on the Specialist Fund Segment of the main market of the London Stock Exchange and are intended for institutional, professional, professionally advised and knowledgeable investors primarily seeking exposure to private mid-market UK and Western European businesses through investment in the Oakley Capital Private Equity funds (or successor funds) and: (a) who understand and are willing to assume the potential risks of capital loss associated with investments in such companies, (b) who understand the illiquid nature of private equity compared to other asset classes, (c) for whom an investment in OCI’s shares would be of a long-term nature constituting part of a diversified portfolio, and (d) who understand, or who have been advised of, the potential risk from investing in companies admitted to the Specialist Fund Segment.

OCI is not subject to the UK City Code on Takeover and Mergers.

Accuracy of information and availability of website

This website and its contents are made available on an “as is” and “as available” basis. OCI uses reasonable efforts to ensure that the information on this website is accurate, but OCI and its personnel and agents disclaim and exclude (to the fullest extent permitted by law) all warranties, representations or guarantees (whether express, implied or statutory) that the information is complete, accurate, up-to-date or suitable for a particular purpose. All documents have their own shelf life and may be included on this website for historical reference purposes only. Any opinions, recommendations and forecasts provided are not necessarily the current opinions, recommendations and forecasts of OCI or any contributors and may be changed at any time. Actual outcomes or results may differ materially from those expressed or implied by any forecast. You agree that access to, and reliance on, this website and any information contained on it is entirely at your own risk.

General

The full terms governing your use of this website are available via the “Legal” link at the foot of each page of the website.  If you proceed to access the website, please read the full terms carefully.

These terms of access (and any dispute, controversy, proceedings or claim of whatever nature arising out of or in any way relating thereto) shall be governed by English law. You agree that the courts of England shall have exclusive jurisdiction over any dispute arising out of or in connection with this website or these terms of access.

By clicking the “I accept” button below, you represent, warrant and agree that:

1. you shall be bound by the terms of access above;

2. (if you are located outside the United Kingdom) the applicable laws and regulations of your jurisdiction allow you to access this website and the information contained within it; and

3. you will not seek to acquire shares of OCI if you are a US Person except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and in compliance with any applicable securities laws of any state or other jurisdiction of the United States and in a manner which would not require OCI to register under the US Investment Company Act of 1940 (as amended).

If you cannot represent, warrant and agree to the above, you must click the button labelled “I disagree” or otherwise exit this website.

WindStar Medical is a unique OTC platform in a highly attractive space that Oakley is excited to be investing in, having closely followed both the development of the business and management over recent years. We look forward to working together with the team and utilising our broad expertise in digitalisation, go-to-market and M&A to help WindStar Medical accelerate its growth trajectory in Germany and international markets.
Peter Dubens
Managing Partner of Oakley Capital
22 Oct 20

Oakley Capital (“Oakley”) is pleased to announce that it has agreed to acquire WindStar Medical GmbH (“WindStar Medical”) from ProSiebenSat.1 majority-owned NuCom Group.

WindStar Medical is Germany’s leading over-the-counter (“OTC”) consumer healthcare company. The platform, which is expected to generate over €120 million in revenues this year, designs, develops and commercialises branded consumer health and private label products, with a track record of establishing best-in-class medical formulations and brands.

The Consumer Brands segment of WindStar Medical offers a wide range of premium high-growth branded products in Germany, including SOS (wound care / disinfectants), Zirkulin (gastro-intestinal care), GreenDoc (mental wellbeing) and EyeMedica (eye health). WindStar Medical is also a provider of Private Label products to the leading German drug stores and supermarkets, whilst also developing an international distribution footprint through existing and new partners.

WindStar Medical benefits from the long-term structural growth of Germany’s consumer health market. This growth is being driven both by demographic trends, such as an ageing population, and a shift in consumer preferences driven by factors such as increased awareness of physical and mental wellbeing and willingness to prevent illness. Through its investment, Oakley will support the company’s management team as they continue to drive revenue growth, product innovation, digitalisation, as well as identifying opportunities to scale the business through accretive acquisitions.

The investment in WindStar Medical builds on Oakley’s successful track record of investing in leading consumer platforms in the DACH region, including Verivox, Parship Elite and more recently Wishcard Technologies and 7NXT / Gymondo. The business displays the typical Oakley deal characteristics, as it has an asset-light business model, industry-leading operational capabilities, and an attractive growth profile.

WindStar Medical is a unique OTC platform in a highly attractive space that Oakley is excited to be investing in, having closely followed both the development of the business and management over recent years. We look forward to working together with the team and utilising our broad expertise in digitalisation, go-to-market and M&A to help WindStar Medical accelerate its growth trajectory in Germany and international markets.
Peter Dubens
Managing Partner of Oakley Capital